SPG601 found to reduce measure of abnormal brain activity in fragile X
FDA Grants Fast Track Designation to Spinogenix’s SPG601 for Treatment of FXS
FDA Designation for SPG601 Highlights New Hope for FXS Treatment
Novel BK Channel Activator Fast Tracked for Fragile X Syndrome
Personalized medicine; astroglia organoids; fast track for fragile X drug
Spinogenix’s SPG601 Receives FDA Fast Track Designation for Fragile X Syndrome
FDA grants fast-track designation to small molecule for Fragile X
FDA grants orphan designation to Fragile X syndrome therapeutic
Spinogenix’s SPG601 Earns Orphan Drug Designation for Fragile X Syndrome
Spinogenix Announces U.S. FDA Orphan Drug Designation Granted to SPG601 for the Treatment of Fragile X syndrome
Press Release Spinogenix Announces U.S. FDA Orphan Drug Designation Granted to SPG601 for the Treatment of Fragile X syndrome Receiving Orphan Drug Designation for SPG601 emphasizes the pressing demand for novel therapies for individuals living with Fragile X syndrome LOS ANGELES, Calif., May 20, 2024 — Spinogenix, Inc., a clinical-stage biopharmaceutical company pioneering first-in-class therapeutics […]
